Ex-Key CEO Michael Jaharis
Executive Summary
Seeking to acquire pharmaceutical products with "immediate marketing opportunities" to build sales force for new company, Kos Pharmaceuticals. Kos has seven products under development, all current compounds with new or improved delivery systems, primarily cardiovascular products. The Miami-based firm expects all seven to be in Phase III trials by end of 1991. Former Key Chief Operating Officer Daniel Bell is president of Kos; ex-Key Product Development Director Dave Bova is VP-R&D. Kos has a 10,000 sq. ft. R&D facility and is also sponsoring research at Tufts University School of Medicine to develop new indications for current drugs. Jaharis is Schering-Plough's largest individual shareholder.